FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 347:1256-1261 October 17, 2002 Number 16 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Treatment of hypertension in patients with normal renal function does not generally cause renal dysfunction. By contrast, in patients with hypertension and chronic renal insufficiency, it is not uncommon for the serum creatinine concentration to rise as the blood pressure is lowered. This complication is likely to be encountered more often since the guidelines governing adequate blood-pressure control have been made more stringent.^1,2 For many physicians, the initial response to a deterioration in renal function is to decrease the dose of antihypertensive medications. This approach is based on the belief that the kidney has been affected by an adverse event . . . [Full Text of this Article]

Renal Autoregulation

Renal Autoregulation in Chronic Hypertension

Renal Dysfunction and Specific Antihypertensive Drugs

ACE Inhibitors

Angiotensin-Receptor Blockers

Diuretics

Calcium-Channel Blockers

Beta-Blockers and Other Classes of Antihypertensive Drugs

Hyperkalemia as a Complication of Antihypertensive Therapy

Source Information

From the Department of Medicine, Division of Nephrology, University of Texas Southwestern Medical School, Dallas.

Address reprint requests to Dr. Palmer at the Department of Medicine, Division of Nephrology, University of Texas Southwestern Medical School, 5323 Harry Hines Blvd., Dallas, TX 75390-8856, or at biff.palmer@utsouthwestern.edu.

This article has been cited by other articles:

• Parving, H.-H., Persson, F., Lewis, J. B., Lewis, E. J., Hollenberg, N. K., the AVOID Study Investigators, (2008). Aliskiren Combined with Losartan in Type 2 Diabetes and Nephropathy. NEJM 358: 2433-2446 [Abstract] [Full Text]  
• Nohria, A., Hasselblad, V., Stebbins, A., Pauly, D. F., Fonarow, G. C., Shah, M., Yancy, C. W., Califf, R. M., Stevenson, L. W., Hill, J. A. (2008). Cardiorenal Interactions: Insights From the ESCAPE Trial. J Am Coll Cardiol 51: 1268-1274 [Abstract] [Full Text]  
• Steinman, T. I. (2008). Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 23: 431-433 [Full Text]  
• Abuelo, J. G. (2007). Normotensive Ischemic Acute Renal Failure. NEJM 357: 797-805 [Full Text]  
• Minutolo, R., Borrelli, S., Scigliano, R., Bellizzi, V., Chiodini, P., Cianciaruso, B., Nappi, F., Zamboli, P., Conte, G., De Nicola, L. (2007). Prevalence and clinical correlates of white coat hypertension in chronic kidney disease. Nephrol Dial Transplant 22: 2217-2223 [Abstract] [Full Text]  
• Smellie, W S A, Forth, J, Coleman, J J, Irvine, W, Dore, P C, Handley, G, Williams, D G, Galloway, P J, Kerr, K G, Herriot, R, Spickett, G P, Reynolds, T M (2007). Best practice in primary care pathology: review 6. J. Clin. Pathol. 60: 225-234 [Abstract] [Full Text]  
• Kambham, N., Nagarajan, S., Shah, S., Li, L., Salvatierra, O., Sarwal, M. M. (2007). A Novel, Semiquantitative, Clinically Correlated Calcineurin Inhibitor Toxicity Score for Renal Allograft Biopsies. CJASN 2: 135-142 [Abstract] [Full Text]  
• Martin, U., Coleman, J. J (2006). Monitoring renal function in hypertension.. BMJ 333: 896-899 [Full Text]  
• Rosner, M. H., Okusa, M. D. (2006). Acute Kidney Injury Associated with Cardiac Surgery. CJASN 1: 19-32 [Abstract] [Full Text]  
• Gil, P., Justo, S., Caramelo, C. (2005). Cardio-renal failure: an emerging clinical entity. Nephrol Dial Transplant 20: 1780-1783 [Full Text]  
• Sharma, K., Cook, A., Smith, M., Valancius, C., Inscho, E. W. (2005). TGF-{beta} impairs renal autoregulation via generation of ROS. Am. J. Physiol. Renal Physiol. 288: F1069-F1077 [Abstract] [Full Text]  
• Main, J. (2005). Atherosclerotic renal artery stenosis, ACE inhibitors, and avoiding cardiovascular death. Heart 91: 548-552 [Full Text]  
• Bidani, A. K., Griffin, K. A. (2004). Pathophysiology of Hypertensive Renal Damage: Implications for Therapy. Hypertension 44: 595-601 [Abstract] [Full Text]  
• Palmer, B. F. (2004). Managing Hyperkalemia Caused by Inhibitors of the Renin-Angiotensin-Aldosterone System. NEJM 351: 585-592 [Full Text]  
• Mange, K. C., Feldman, H. I., Joffe, M. M., Fa, K., Bloom, R. D. (2004). Blood Pressure and the Survival of Renal Allografts from Living Donors. J. Am. Soc. Nephrol. 15: 187-193 [Abstract] [Full Text]  
• Palmer, B. F. (2003). Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what to do if the serum creatinine and/or serum potassium concentration rises. Nephrol Dial Transplant 18: 1973-1975 [Full Text]  
• Sharma, A.M. (2003). Renal involvement in hypertensive cardiovascular disease. Eur Heart J Suppl 5: F12-F18 [Abstract]  
• Fukuda, M., Usami, T., Yoshida, A., Kimura, G. (2003). Antihypertensive Drugs and Renal Protection. JAMA 289: 1102-1103 [Full Text]